# Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML

> **NCT05456048** · — · COMPLETED · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 231 (actual)

## Conditions studied

- Relapsed Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Gene Abnormality
- Cytogenetic Abnormality

## Interventions

- **DRUG:** VAH regimen
- **DRUG:** VEN+HMA regimen

## Key facts

- **NCT ID:** NCT05456048
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-03
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-05-31
- **Target enrollment:** 231 (ACTUAL)
- **Last updated:** 2022-07-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05456048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05456048, "Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05456048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*